An analysis explores cytokine release syndrome in relapsed/refractory multiple myeloma, indicating management strategies.
[Introduction] Cytokine release syndrome (CRS) is a common adverse event associated with T-cell redirection therapies (TCRT), including talquetamab, the first GPRC5D × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). We describe CRS with talquetamab and implications for clinical practice.
No takes yet. Share an insight, caveat, or question.
Donk et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: